EPRX Stock Summary and Trading Ideas (Eupraxia Pharmaceuticals | NASDAQ:EPRX)

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Eupraxia Pharmaceuticals trades on the NASDAQ stock market under the symbol EPRX.

As of July 2, 2026, EPRX stock price declined to $6.69 with 349,897 million shares trading.

EPRX has a beta of 1.34, meaning it tends to be more sensitive to market movements. EPRX has a correlation of 0.13 to the broad based SPY ETF.

EPRX has a market cap of $437.04 million. This is considered a Small Cap stock.

EPRX has outperformed the market in the last year with a price return of +24.1% while the SPY ETF gained +21.3%. However, in the short term, EPRX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.7% vs +13.9% return in SPY. But in the last 2 weeks, EPRX shares have fared better than the market returning +3.2% compared to SPY -0.3%.

EPRX support price is $6.41 and resistance is $7.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EPRX shares will trade within this expected range on the day.